NO20075985L - Stabil emulsjonsforbindelse - Google Patents

Stabil emulsjonsforbindelse

Info

Publication number
NO20075985L
NO20075985L NO20075985A NO20075985A NO20075985L NO 20075985 L NO20075985 L NO 20075985L NO 20075985 A NO20075985 A NO 20075985A NO 20075985 A NO20075985 A NO 20075985A NO 20075985 L NO20075985 L NO 20075985L
Authority
NO
Norway
Prior art keywords
stable emulsion
emulsion compound
compound
stable
buffer
Prior art date
Application number
NO20075985A
Other languages
English (en)
Norwegian (no)
Inventor
Naoki Asakawa
Takayuki Doen
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075985(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20075985L publication Critical patent/NO20075985L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
NO20075985A 2005-04-28 2007-11-21 Stabil emulsjonsforbindelse NO20075985L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005131807 2005-04-28
PCT/JP2006/309213 WO2006118329A1 (fr) 2005-04-28 2006-04-27 Préparation de type émulsion stable

Publications (1)

Publication Number Publication Date
NO20075985L true NO20075985L (no) 2008-01-25

Family

ID=37308111

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075985A NO20075985L (no) 2005-04-28 2007-11-21 Stabil emulsjonsforbindelse

Country Status (24)

Country Link
US (1) US20100016381A1 (fr)
EP (2) EP1875926A4 (fr)
JP (2) JP5236287B2 (fr)
KR (1) KR101321633B1 (fr)
CN (2) CN101212986B (fr)
AR (1) AR054264A1 (fr)
AU (1) AU2006241671B2 (fr)
BR (1) BRPI0610029A2 (fr)
CA (1) CA2605773C (fr)
CR (2) CR9495A (fr)
GE (1) GEP20105031B (fr)
IL (1) IL186673A (fr)
MA (1) MA29487B1 (fr)
ME (1) MEP10209A (fr)
MX (1) MX2007013407A (fr)
MY (1) MY147790A (fr)
NO (1) NO20075985L (fr)
NZ (1) NZ563225A (fr)
PE (1) PE20061437A1 (fr)
RU (1) RU2428204C2 (fr)
TW (1) TWI462745B (fr)
UA (1) UA97346C2 (fr)
WO (1) WO2006118329A1 (fr)
ZA (1) ZA200710193B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007132825A1 (ja) * 2006-05-15 2009-09-24 武田薬品工業株式会社 医薬
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
CN101229174B (zh) * 2008-01-25 2010-12-15 广东一品红药业有限公司 一种含有盐酸依匹斯汀的抗过敏组合物
US7829513B2 (en) * 2009-03-12 2010-11-09 Greenology Products, Inc. Organic cleaning composition
SG10201503402XA (en) 2010-01-27 2015-06-29 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
JP2012214430A (ja) * 2011-03-31 2012-11-08 Fujifilm Corp プロスタグランジン含有脂肪乳剤
JP5894752B2 (ja) * 2011-03-31 2016-03-30 富士フイルム株式会社 プロスタグランジン含有脂肪乳剤
CN103458929A (zh) * 2011-03-31 2013-12-18 富士胶片株式会社 含有前列腺素的脂肪乳剂
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (fr) 2013-11-06 2017-05-31 Aeromics, Inc. Nouvelles formulations
US20170246136A1 (en) * 2014-09-24 2017-08-31 OliVentures, Inc. Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases
EP3454891A4 (fr) 2016-05-10 2019-12-25 The Regents of The University of Michigan Adjuvant en émulsion pour administration intramusculaire, intradermique et sous-cutanée
WO2021252449A1 (fr) * 2020-06-08 2021-12-16 Harm Reduction Therapeutics, Inc. Formulations stérilisées

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128339A (en) * 1990-11-01 1992-07-07 Sterling Winthrop Inc. Proteolytic enzyme inhibition method
US5380737A (en) * 1989-05-04 1995-01-10 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
AU642537B2 (en) * 1990-11-01 1993-10-21 Sanofi 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5306818A (en) * 1990-11-01 1994-04-26 Sterling Winthrop Inc. Tetrahydro 2-saccharinylmerthyl aryl carboxylates
US5250696A (en) * 1990-11-01 1993-10-05 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylate
US5512589A (en) * 1990-11-01 1996-04-30 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JP2836599B2 (ja) 1996-08-09 1998-12-14 日本電気株式会社 通信制御装置
DK1063228T5 (da) * 1998-03-09 2009-06-15 Takeda Pharmaceutical Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf
CN1170959C (zh) 1998-03-11 2004-10-13 三菱电机株式会社 放电表面处理用压粉体电极
WO2001010826A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. Composes a cycle aromatique substitues, procede de production, et utilisation
US6532316B1 (en) * 1999-11-10 2003-03-11 Avanex Corporation Bi-directional polarization-independent optical isolator
JP4863553B2 (ja) * 2000-02-04 2012-01-25 武田薬品工業株式会社 安定な乳化組成物
CN1416341B (zh) * 2000-02-04 2010-05-05 武田药品工业株式会社 稳定的乳液组合物
JP2003033195A (ja) * 2001-07-24 2003-02-04 Kyowa Hakko Kogyo Co Ltd テトラヒドロクルクミン類の製造方法
JP5137289B2 (ja) * 2001-08-03 2013-02-06 武田薬品工業株式会社 安定な乳化組成物
US20030220284A1 (en) * 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
JPWO2004052354A1 (ja) * 2002-12-06 2006-04-06 株式会社大塚製薬工場 プロポフォール含有脂肪乳剤
WO2005032536A1 (fr) * 2003-10-03 2005-04-14 Ono Pharmaceutical Co., Ltd. Medicament contenant un acide (2r)-2-propyloctanoique comme principe actif
JPWO2007123186A1 (ja) * 2006-04-20 2009-09-03 武田薬品工業株式会社 医薬

Also Published As

Publication number Publication date
MEP10209A (en) 2011-12-20
JPWO2006118329A1 (ja) 2008-12-18
CR20130666A (es) 2014-03-13
MY147790A (en) 2013-01-31
RU2007144071A (ru) 2009-06-10
RU2428204C2 (ru) 2011-09-10
PE20061437A1 (es) 2007-01-25
CA2605773C (fr) 2014-04-08
MX2007013407A (es) 2008-01-15
MA29487B1 (fr) 2008-05-02
KR101321633B1 (ko) 2013-10-22
CN101212986A (zh) 2008-07-02
AR054264A1 (es) 2007-06-13
NZ563225A (en) 2011-01-28
JP2013040215A (ja) 2013-02-28
CN102670503A (zh) 2012-09-19
ZA200710193B (en) 2009-07-29
IL186673A0 (en) 2008-01-20
EP1875926A4 (fr) 2013-01-16
IL186673A (en) 2013-08-29
BRPI0610029A2 (pt) 2011-10-11
US20100016381A1 (en) 2010-01-21
CN101212986B (zh) 2015-01-14
EP1875926A1 (fr) 2008-01-09
GEP20105031B (en) 2010-06-25
AU2006241671B2 (en) 2012-06-07
EP2255785A3 (fr) 2013-01-16
UA97346C2 (ru) 2012-02-10
TW200724159A (en) 2007-07-01
JP5236287B2 (ja) 2013-07-17
EP2255785A2 (fr) 2010-12-01
CR9495A (es) 2008-02-22
WO2006118329A1 (fr) 2006-11-09
CA2605773A1 (fr) 2006-11-09
TWI462745B (zh) 2014-12-01
AU2006241671A1 (en) 2006-11-09
KR20080011413A (ko) 2008-02-04

Similar Documents

Publication Publication Date Title
AR116860A2 (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
CY1122370T1 (el) Συνθεσεις που περιεχουν φθοριο yποκατeστημενες ολεφινες
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
CO5720212A1 (es) Composicion de anticuerpo her2
CR9495A (es) Composicion en emulsion estable
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
AR109135A2 (es) Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv
DK1720909T3 (da) Anti-Abeta antistof
NO20074179L (no) Prodrugs av 2,4-pyrimidindiaminforbindelser og deres anvendelse
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200970112A1 (ru) Документ, снабженный идентифицирующими и верификационными данными
NO20071823L (no) Testosterongeler omfattende polypropylenglykol som gjennomtrengningsforsterker
CY1111390T1 (el) Μεθοδος θεραπευτικης αγωγης καρκινου
NO20052529L (no) Forbindelse og sammensetning, og anvendelse av samme
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
NO20060021L (no) Trelim
EA200801351A1 (ru) Фунгицидные смеси, которые содержат боскалид и пириметанил
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
NO20065451L (no) Dermalt anvendbare flytende formuleringer for a kontrollere parasittartropoder pa dyr.
EA201000566A1 (ru) Гетероциклические сетр ингибиторы
NO20074805L (no) Fremgangsmate for a identifisere PDE11-modulatorer
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application